Drugs / Trineumin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07131722 | Jul 2026 → Jul 2028 expected | NF2-related schwannomatosis | PRG Science & Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trineumin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07131722 ↗ |
| Known as | PRG-N-01 | “Trineumin(Code name: PRG-N-01) is administered orally once daily.” NCT07131722 ↗ |
| Route | Oral | “Trineumin is administered orally once daily.” NCT07131722 ↗ |